EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 billion deal By Reuters
By Foo Yun Chee and Maggie Fick BRUSSELS/LONDON (Reuters) – EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings’ planned $16.5 billion takeover of Catalent (NYSE:), people familiar with the matter said. Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk (NYSE:), whose profits from blockbuster weight-loss drug Wegovy propelled it to become Europe’s most valuable company